Semax is often filed under the loose category of “Russian nootropics,” but that label obscures what is genuinely interesting about the molecule: it is a rationally designed fragment of adrenocorticotropic hormone (ACTH) — specifically the ACTH(4-10) sequence — engineered to retain the neurotropic effects of the parent hormone while stripping away its corticosteroid-releasing activity. The result is a heptapeptide that engages the brain’s melanocortin signaling system, a pathway better known for regulating appetite and pigmentation, and uses it to amplify BDNF expression and tune prefrontal dopaminergic tone.
What Is Semax?
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, corresponding to ACTH(4-7) extended with a Pro-Gly-Pro tripeptide at the C-terminus. The Pro-Gly-Pro extension dramatically increases enzymatic stability, extending the peptide’s half-life from minutes (as seen with native ACTH fragments) to hours. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s and has been registered in the Russian Federation for clinical use in ischemic stroke, optic nerve atrophy, and cognitive disorders.[1]
Unlike most peptides considered for cognitive applications, Semax is administered intranasally — a route that exploits the olfactory and trigeminal pathways to deliver peptide directly into the central nervous system, bypassing the blood-brain barrier. Pharmacokinetic studies in rodents demonstrate detectable peptide concentrations in brain tissue within minutes of intranasal administration.[1]
How Semax Works
Melanocortin Receptor Engagement: Semax retains the core ACTH(4-10) pharmacophore that binds melanocortin receptors, particularly MC4R, which is densely expressed in the hypothalamus, hippocampus, and cortex. Critically, because Semax lacks the N-terminal residues of full-length ACTH, it does not stimulate the adrenal cortex or elevate cortisol — separating the neurotrophic actions of the melanocortin system from its endocrine effects.[2]
BDNF and NGF Upregulation: The most reproducible molecular effect of Semax is rapid upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in the basal forebrain and hippocampus. Shadrina and colleagues demonstrated that a single intranasal dose of Semax increases BDNF and NGF mRNA in rat hippocampus and frontal cortex within 3 hours, with sustained TrkA and TrkB receptor activation.[3] This neurotrophic surge is thought to underlie the peptide’s effects on synaptic plasticity and neuronal survival following ischemic insult.
Dopaminergic Modulation: Semax exerts a region-specific modulation of dopaminergic tone. Rodent microdialysis studies show that intranasal Semax increases extracellular dopamine and its metabolites in the striatum and prefrontal cortex, with concurrent inhibition of enkephalin-degrading enzymes that prolongs endogenous opioid signaling.[4] This combined dopaminergic and enkephalinergic effect distinguishes Semax from monoaminergic stimulants — it does not flood synapses with dopamine but rather elevates baseline tone in circuits relevant to attention, motivation, and working memory.
Antioxidant and Anti-inflammatory Effects: Beyond direct receptor engagement, Semax has been shown to modulate gene expression programs related to oxidative stress and neuroinflammation. Transcriptomic analyses in models of focal cerebral ischemia demonstrate that Semax administration alters expression of hundreds of genes involved in immune response, vascular function, and neurotransmitter signaling.[5]
Clinical Evidence
Ischemic Stroke: The most rigorous clinical data on Semax come from its use in acute ischemic stroke. A multicenter Russian trial reported that intranasal Semax administered within the first hours of stroke onset reduced neurological deficit scores and improved functional outcomes at 30 days compared to standard care, with the effect most pronounced in moderate-to-severe strokes.[1] The proposed mechanism combines BDNF-mediated neuroprotection in the penumbra with anti-inflammatory effects on infiltrating leukocytes.
Cognitive and Executive Function: In healthy human volunteers and patients with cognitive complaints, Semax has been investigated for effects on attention, working memory, and executive function. Studies using event-related potentials report enhanced P300 amplitude and reduced latency following Semax administration — electrophysiological signatures associated with attentional allocation and working memory updating.[2] The effects appear most pronounced under conditions of fatigue or cognitive load, consistent with a tone-modulating rather than overtly stimulant pharmacology.
Optic Nerve and Retinal Pathology: Semax is registered in Russia for optic nerve atrophy and is used adjunctively in glaucomatous neuropathy. The rationale rests on retinal ganglion cell dependence on BDNF/TrkB signaling for survival, and on direct evidence that Semax preserves retinal ganglion cells in experimental optic nerve injury models.[3]
Safety Profile
Semax has accumulated decades of clinical use in the Russian Federation, primarily as a 0.1% or 1% intranasal solution. Reported adverse events are uncommon and generally mild: transient nasal irritation, occasional headache, and rare reports of insomnia or anxiety with higher doses. Because the peptide does not engage MC2R (the adrenal melanocortin receptor) and lacks the N-terminal residues required for steroidogenesis, it does not produce the cortisol elevations or HPA-axis disruption seen with full-length ACTH or cosyntropin.[2]
Important caveats: Semax is not FDA-approved, and most safety data derive from Russian clinical literature with variable methodological standards. Long-term controlled safety data in healthy users — particularly relating to chronic melanocortin receptor engagement — are limited. Theoretical concerns about MC4R activation include potential effects on appetite regulation and sexual function, though these have not emerged as prominent clinical signals at standard doses.
Semax vs Other Neurotrophic Approaches
Versus Cerebrolysin: Both agents aim to amplify endogenous neurotrophic signaling, but through different routes. Cerebrolysin is a porcine brain-derived peptide mixture administered intravenously or intramuscularly, providing a heterogeneous cocktail of neuropeptides. Semax is a single defined heptapeptide administered intranasally, with a more circumscribed and characterized mechanism centered on melanocortin receptor signaling and BDNF induction.
Versus Direct BDNF Mimetics: Small-molecule TrkB agonists (such as 7,8-dihydroxyflavone) attempt to bypass BDNF entirely by directly activating its receptor. Semax instead works upstream — increasing endogenous BDNF expression and allowing physiological spatial and temporal regulation of TrkB signaling. The trade-off is slower onset and dependence on intact transcriptional machinery; the advantage is preservation of normal feedback regulation.
Versus Stimulant Nootropics: Methylphenidate and modafinil increase prefrontal dopaminergic and noradrenergic signaling through transporter inhibition or reuptake antagonism. Semax produces a more modest dopaminergic effect coupled with neurotrophic and anti-inflammatory actions, and lacks the cardiovascular and dependence liabilities associated with monoaminergic stimulants. It is better understood as a tone-modulator that acts through trophic and receptor-level mechanisms rather than as an acute performance enhancer.
Versus Selank: Selank, another Russian-developed heptapeptide derived from tuftsin, is often discussed alongside Semax. While both are intranasal heptapeptides, Selank’s primary actions involve GABAergic and serotonergic modulation with anxiolytic effects, whereas Semax centers on melanocortin signaling and dopaminergic-cholinergic enhancement. The two represent complementary rather than overlapping pharmacologies.
Summary
Semax illustrates how a deliberately truncated fragment of a classical hormone can be repurposed to access one branch of its signaling biology — in this case, the neurotrophic and behavioral arms of the melanocortin system — while leaving its endocrine effects behind. Its combination of MC4R engagement, BDNF induction, and modest prefrontal dopaminergic modulation positions it as a mechanistically distinct tool among cognitive peptides. The strongest evidence supports its use in acute ischemic stroke; the data on healthy cognitive enhancement remain preliminary and would benefit from rigorous Western-standard trials.
References
- Gusev EI, Skvortsova VI, Miasoedov NF, et al. “Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study).” Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 1997;97(6):26-34.
- Kaplan AY, Kochetova AG, Nezavibathko VN, Rjasina TV, Ashmarin IP. “Synthetic ACTH analogue Semax displays nootropic-like activity in humans.” Neuroscience Research Communications. 1996;19(2):115-123.
- Shadrina MI, Dolotov OV, Grivennikov IA, et al. “Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog.” Neuroscience Letters. 2001;308(2):115-118.
- Eremin KO, Kudrin VS, Saransaari P, et al. “Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents.” Neurochemical Research. 2005;30(12):1493-1500.
- Medvedeva EV, Dmitrieva VG, Povarova OV, et al. “The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis.” BMC Genomics. 2014;15:228.
